Goodwin Guides Oblenio Bio on Closing $62 Million Series B

The Life Sciences team advised Oblenio Bio (“Oblenio”) on the closing of an oversubscribed $62 million Series B financing round, positioning the company as an emerging leader in the treatment of autoimmune disease. The round was led by Pfizer Ventures, with participation from new investors Deep Track Capital and GV, alongside Aditum Bio, Oblenio’s founding and Series A investor. The Series B proceeds will be used for the initial clinical development of LBL-051, Oblenio’s tri-specific T cell engager, designed to achieve a broad immune system reset to treat patients suffering from a range of refractory autoimmune diseases. LBL-051 unites validated targets BCMA, CD19, and CD3 and is specifically engineered for autoimmune patients. 

Oblenio Bio is pursuing broad immune reset as a transformative therapy for refractory autoimmune diseases through its LBL-051 T cell engager. Specifically engineered for autoimmune patients, Oblenio’s tri-specific unites validated targets BCMA, CD19, and CD3 to safely and completely deplete B cells and plasma cells to achieve long-term drug-free remission. Led by proven drug developers and industry leaders, Oblenio Bio is singularly focused on LBL-051’s groundbreaking clinical development program to rapidly establish it as a life-changing treatment for the vast number of patients who endure severe autoimmune disease without relief.

The Goodwin team was led by Gaby Morales-Rivera, Beth Nelson, Hugh Rennie, Ankit Gupta, and Bill Collins. 

For more information on the deal, please read the press release.